Get even more insights on these trends and the topics that matter most to manufacturers at KnowledgeDriven.com.
WHAT DO PAYERS THINK ABOUT
Full results presented at the 2016 Academy of Managed Care Pharmacy Annual Meeting and Partners Healthcare Connected Health Symposium, and can be found here.
Here's what we found.
AmerisourceBergen’s strategic consulting experts at Xcenda conducted a double-blinded online questionnaire to survey 61 payer decision-makers from plans that cover approximately 180 million lives in the U.S. We asked them to share their perspective on nine categories of DHTs to help us understand how they’re looking at digital health.
Mobile apps, fitness trackers, biometric monitors … digital health technologies (DHTs) could revolutionize how we approach our health, as well as how we access healthcare services.
Payers are evaluating DHTs for
their members, and see potential in eventual implementation.
All numbers reflect percentage of total payer respondents
POINT OF CARE DIAGNOSTICS
Medication Adherence Platforms
Continuous biotech monitors
Top DHTs with open coverage
Top DHTs with some form of coverage or evaluated
Disease states where DHTs could create the most impact:
Fitness trackers and
platforms were lowest at 13%
Home vital monitors were highest at 46%
No DHT had coverage (including open and restricted) that approached
Drug-delivery device combinations can improve outcomes by making it easier for patients to administer therapies correctly …
and fewer than 25% have open or restricted coverage for them.
but only 49% of surveyed payers ranked them among the top 3 for demanded DHTs ...
of surveyed payers ranked mobile apps among their top 3 DHTs demanded by member populations...
but only 13% of surveyed payers cover them.
Payers recognize the impact of medication adherence on health outcomes, and most payers identify interest from their member population (57%) in adherence DHTs …
but almost 69% of surveyed payers do not cover them.
and mobile apps had the highest rate of open coverage (18%) among all DHTs evaluated …
Despite the recognition of potential impact, a chasm exists between payer interest and payer coverage.
Overall economic value
Prospective randomized controlled trial
Most influential evaluation strategies for
Top outcome types used to evaluate DHTs
Top criteria used to evaluate DHTs as a member benefit
All numbers above reflect % of surveyed payers that selected the option among their top 3 answers for each question.
To cross this chasm, DHT manufacturers need to learn the language of payers …
Numbers above reflect % of surveyed payers that selected the option given the chance to choose all that apply
from a list of strategies.
… and then speak the language of payers where payers are most inclined to listen.
Dedicated peer-reviewed journals
sessions at conferences
Advisory board meetings
Top communication strategies
Vice President, Strategic Market Insights
Senior Vice President, Scientific Consulting
Already planning to launch a DHT?
Talk to us about how to design a market access strategy that includes an effective clinical and health economic message, as well as the optimal mix of communication strategies that drive awareness and action from the payer community.
Access more detailed findings from our survey
including the top evaluation strategies payers use to select coverage determination—in our scientific poster here, which was presented at the 2016 Academy of Managed Care Pharmacy Annual Meeting and Partners Healthcare Connected Health Symposium.
How confident are you in your ability to launch a DHT effectively?
Test yourself in our interactive challenge today.
but getting there requires the proven and disciplined value measurement and payer engagement methods that pharma has used successfully for years.
may be the future ...